BackNovo Nordisk A/S Class B Overview

Novo Nordisk A/S Class B Accounts Payable

Novo Nordisk A/S Class B's accounts payable is $15B.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$15.22B
↓ 36.34% YoYΔ $-8.69B vs prior year quarter

Peer trimmed avg / median

Loading

Novo Nordisk A/S Class B Accounts Payable History

Loading

Novo Nordisk A/S Class B vs. peers: Accounts Payable Comparison

Loading

Novo Nordisk A/S Class B Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Novo Nordisk A/S Class B (NONOF) FAQ

Novo Nordisk A/S Class B (NONOF) currently reports a accounts payable of $15B as of September 2026. That compares with $24B in the prior-year period — down 36.3% year over year. Use the charts on this page to explore Novo Nordisk A/S Class B's accounts payable history and peer comparisons.

Novo Nordisk A/S Class B's accounts payable decreased from $24B to $15B — a 36.3% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Novo Nordisk A/S Class B reported $15B in accounts payable as of September 2026. That compares with $24B in the prior-year period — down 36.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $15B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Novo Nordisk A/S Class B, and consider following NONOF for alerts when major investors trade the stock.

Novo Nordisk A/S Class B is classified in the Healthcare sector. On accounts payable, it currently shows $15B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NONOF with unrelated industries.